Validation and Adaptation of the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59 Items Revised into Turkish

Ordin, Yaprak Sarıgöl; Çilengiroğlu, Özgül Vupa

doi:10.7182/pit2013743

Cited by 7 publications

(28 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Turkish validity and reliability study of MTSOSD-59 was performed by Ordin and associates in 2013. 24 Content validity was evaluated using the Content validity index (Content validity index = 1.0). After the content validity of the Turkish version of the instrument was established, it was called MTSOSD-58 because it included 58 items.…”

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

“…The reliability of the scale was tested with the split half method and was found to be good in symptom occurrence (0.919) and symptom distress (0.920) dimensions. 24 We determined the most frequently occurring and most distressing adverse effects using ridit analysis.…”

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

“…Symptom occurrence is assessed on a 5-point rating scale ranging from 0 (never occurring) to 4 (always occurring), and symptom distress is also assessed on a 5-point rating scale ranging from 0 (not at all distressing) to 4 (extremely distressing). 23,24 Beck depression inventory Beck Depression Inventory (BDI) was developed by Beck in 1961, 25 and is a reliable and valid instrument used in diverse populations, including transplant recipients. 24 The Beck Depression Inventory was adapted into Turkish in 1998 by Hisli 26 and shown to have acceptable reliability and validity.…”

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

See 2 more Smart Citations

Untitled

Ordin¹,

Ünek²,

Astarcıoğlu³

2015

Exp Clin Transplant

View full text Add to dashboard Cite

Objectives: This study sought to investigate immunosuppressive medication adherence, therapeutic adherence, school performance, symptom experiences, and depression levels of patients having undergone liver transplant during childhood. Results: While the rate of adherence with clinical appointments was 55.5%, it was 33.3% with the diet (prescribed regime) and 44.4% with exercise. While 33.3% of the participants repeated a grade or were held back, 44.4% of them missed more than 20 school days. Of the symptoms, the recipients mostly experienced anxiety, restlessness, nervousness, fatigue, and difficulty in concentrating. The patients' mean depression score was 7.77 when they were compared to their healthy peers, the difference was not statistically significant (P > .05). Conclusions: In our study, the recipients' adherence with immunosuppressive therapy and clinical appointment was high. This study will provide data for the literature about pediatric liver transplant recipients' adherence with diet and exercise, and physiological and psychological symptoms such as fatigue and anxiety.

show abstract

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

Section: Therapeutic Regimen Assessment Questionnairementioning

confidence: 99%

See 1 more Smart Citation

Untitled

Ordin¹,

Ünek²,

Astarcıoğlu³

2015

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

“…22 A Turkish validity and reliability study was performed by Ordin and associates (2013b). 23 The study was applied to liver and kidney transplant recipients (n = 180) and healthy control subjects (n = 180). The Turkish version of the instrument was translated in a culturally sensitive way using forward-backward translation.…”

Section: Modified Transplant Symptom Occurrence and Symptom Distress mentioning

confidence: 99%

“…The reliability of the scale was tested using the split half method and was found to be good in the symptom occurrence (.919) and symptom distress (.920) dimensions. 23 The Short-Form Health Survey (SF-36) The Short-Form Health Survey (SF-36) is the most frequently used instrument to measure healthrelated quality of life. 5,6 The SF-36 is composed of 35 items and 8 subscales: physical functioning, role physical, bodily pain, vitality, general health, social functioning, role emotion, and mental health.…”

Section: Modified Transplant Symptom Occurrence and Symptom Distress mentioning

confidence: 99%

Untitled

Ordin

2016

Exp Clin Transplant

View full text Add to dashboard Cite

show abstract

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement

Stegall

Somerville

Everly

et al. 2019

American Journal of Transplantation

View full text Add to dashboard Cite

The Transplant Therapeutics Consortium (TTC) is a public-private partnership between the US Food and Drug Administration and the transplantation community including the transplantation societies and members of the biopharmaceutical industry.The TTC was formed to accelerate the process of developing new medical products for transplant patients. The initial goals of this collaboration are the following: (a) To define which aspects of the kidney transplant drug-development process have clear needs for improvement from an industry and regulatory perspective; (b) to define which of the unmet needs in the process could be positively impacted through the development of specific drug-development tools based on available data; and (c) to

show abstract

Validation and Adaptation of the Modified Transplant Symptom Occurrence and Symptom Distress Scale-59 Items Revised into Turkish

Abstract: The results suggest that the Turkish scale has appropriate language, content, and construct validity. This scale can now be used to assess the symptom experience related to immunosuppressive therapy in Turkish organ transplant recipients.

Cited by 7 publications

References 25 publications

Untitled

Untitled

Untitled

The importance of drug safety and tolerability in the development of new immunosuppressive therapy for transplant recipients: The Transplant Therapeutics Consortium’s position statement

Contact Info

Product

Resources

About